Results 1 to 10 of about 1,771 (194)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context [PDF]

Biomedicines, 2021
Dalbavancin is a lipoglycopeptide approved for treatment of Gram-positive infections of skin and skin-associated structures (ABSSSI). Currently, off-label use at high dosages for osteoarticular infections deserves attention.
Amedeo De Nicolò, Giacomo Stroffolini, Miriam Antonucci   +2 more
exaly   +8 more sources

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Therapeutics and Clinical Risk Management, 2016
Kimberly D Leuthner,1 Kristin A Buechler,1 David Kogan,1 Agafe Saguros,1 H Stephen Lee2 1Department of Pharmaceutical Services, University Medical Center of Southern Nevada, Las Vegas, NV, USA; 2Roseman University of Health Sciences College of Pharmacy,
Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS   +4 more
exaly   +6 more sources

Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use. [PDF]

Drugs Context
Background: Oritavancin is a long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) with potential applicability across difficult-to-treat Gram-positive infections such as osteomyelitis ...
Soriano A, Tascini C, Falcone M, Morata L, Bongiovanni M, Pea F, Viale P.   +6 more
europepmc   +2 more sources

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center [PDF]

Antibiotics, 2021
Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of ...
Lucia Brescini, Filippo Della Martera, Gianluca Morroni, Sara Mazzanti, Maria Di Pietrantonio, Paolo Mantini, Bianca Candelaresi, Francesco Pallotta, Silvia Olivieri, Valentina Iencinella, Sefora Castelletti, Emanuele Cocci, Rosaria G. Polo, Salvatore Veccia, Oscar Cirioni, Marcello Tavio, Andrea Giacometti   +16 more
doaj   +3 more sources

Using Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients: A Real-Life, Single-Center Observational Study. [PDF]

Antibiotics (Basel)
Background/Objectives: Obesity is an established risk factor for several infective conditions, including Acute Bacterial Skin and Skin Structure Infections (ABSSSIs), with a rising trend in their incidence expected in this population.
Oliva A, Petrucci F, Leanza C, Rivano Capparuccia M, Comi M, Mastroianni C.   +5 more
europepmc   +2 more sources

Financial Analysis of Dalbavancin for Acute Bacterial Skin and Skin Structure Infections for Self-Pay Patients [PDF]

Infectious Diseases and Therapy, 2020
Introduction Acute bacterial skin and skin structure infections (ABSSSI) are an increasing cause of admission in the self-pay population. We previously reported that patients with ABSSSI discharged to receive dalbavancin showed a decreased length of stay
Adam G. Pizzuti, E. Yancy Murray, Jamie L. Wagner, Derek A. Gaul, Christopher M. Bland, Bruce M. Jones   +5 more
doaj   +3 more sources

Cost-analysis from real-world REDS study on dalbavancin in inpatient treatment of acute bacterial skin and skin structure infections. [PDF]

Glob Reg Health Technol Assess
Introduction: Inpatient treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) involves a significant economic burden on the healthcare system.
Scortichini M, Ruggieri A, Cattaneo A, Mascagni P, Sciattella P.   +4 more
europepmc   +2 more sources

Omadacycline for the treatment of acute bacterial skin and skin structure infections: a systematic review and network meta-analysis. [PDF]

BMC Infect Dis
Background Few studies have compared the efficacy and safety of omadacycline with other treatments for acute bacterial skin and skin structure infections (ABSSSI). Therefore, updated meta-analyses on this topic is necessary.
Kong WQ, Shu YF, Tang J, Li SQ, Zhong H, Zhang XY.   +5 more
europepmc   +2 more sources

Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials. [PDF]

Infect Dis Ther
Introduction Appropriate oral antibiotic therapy for the treatment of acute bacterial skin and skin structure infections (ABSSSI) is a challenge, as current oral treatment guidelines do not fully cover the most common skin pathogens.
Rodriguez GD, Warren N, Yashayev R, Chitra S, Amodio-Groton M, Wright K.   +5 more
europepmc   +2 more sources

Necessity of vancomycin trough concentrations to manage uncomplicated acute bacterial skin and skin structure infections: a laboratory stewardship analysis

Drugs in Context, 2023
Background: Recent recommendations by the American Society of Health System Pharmacists and Infectious Disease Society of America have provided guidance regarding vancomycin dosing and monitoring in serious infections (including methicillin-resistant ...
Andrew Merker, Kartik Anne, Justin Rayyan, Milena Murray   +3 more
doaj   +1 more source